| Selzentry (maraviroc) / ViiV Healthcare |
ACTRN12611000816954: A randomised, open-label study to evaluate the efficacy and safety of maraviroc (MVC) as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART): MARCH study |
|
|
| Recruiting | 4 | 560 | | | University of New South Wales, Kirby Institute, Pfizer Inc., a Delaware Corporation | HIV | | | | |
2010-023625-38: Trial to investigating the effect of Maraviroc on movement of microbes across the gut wall in HIV-1 infected individuals who are receiving antiretroviral therapy |
|
|
| Ongoing | 4 | 10 | Europe | Film-coated tablet, Celsentri film-coated tablets | Guy's and St Thomas' NHS Foundation Trust, ViiV Healthcare UK Ltd. | HIV, HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2013-004809-24: The role of Home packs of HIV PEPSE in High Risk Individuals |
|
|
| Ongoing | 4 | 140 | Europe | Film-coated tablet, Celsentri (Trial Arm A), Truvada (Trial Arm A), Celsentri (Trial Arm B), Truvada (Trial Arm B) | Guy's & St. Thomas' NHS Foundation Trust, Viiv Healthcare UK Ltd, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002134-31: Maraviroc and cardiovascular risk in HIV+ patients. Maraviroc e rischio cardiovascolare in pazienti HIV+. |
|
|
| Ongoing | 4 | 40 | Europe | NA, NA, Film-coated tablet, Celsentri | Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario, Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario | HIV-1 infection. Infezione da HIV-1., HIV-1 HIV-1, Diseases [C] - Virus Diseases [C02] | | | | |
2008-002978-35: Intensification of HAART with Maraviroc (MVC) as first line therapy of HIV-1-infected patients to rapidly suppress viral replication and minimize the evolution of drug-resistant variants |
|
|
| Ongoing | 4 | 20 | Europe | MARAVIROC, | AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE) | First line therapy of HIV-1-infected patients. | | | | |
2008-003635-20: Maraviroc Immune Recovery Study (MIRS):A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recovery |
|
|
| Ongoing | 4 | 130 | Europe | Celsentry, Celsentry | Universitair Medisch Centrum Utrecht | HIV-1 infection | | | | |
2008-006286-80: Evaluación de los niveles farmacológicos de Maraviroc en Líquido Cefalorraquídeo (LCR) y semen en sujetos infectados por el VIH. |
|
|
| Ongoing | 4 | 12 | Europe | Celsentri, Celsentri | Daniel Podzamczer Palter | Infección por VIH | | | | |
2009-014694-40: A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy |
|
|
| Ongoing | 4 | 12 | Europe | | | HIV | | | | |
2010-022202-41: ESTUDIO PILOTO DEL CAMBIO EN LA ACTIVIDADANTIRRETROVIRAL EN SISTEMA NERVIOSO CENTRAL TRAS LA SUSTITUCIÓN DE TDF/FTC/EFV POR ABC/3TC/MVC |
|
|
| Ongoing | 4 | 15 | Europe | CELSENTRI 150 mg comprimidos recubiertos con película, ATRIPLA 600 mg/245 mg comprimidos recubiertos con película, KIVEXA 600 mg/300 mg comprimidos recubiertos con película, CELSENTRI 150 mg comprimidos recubiertos con película, ATRIPLA 600 mg/245 mg comprimidos recubiertos con película, KIVEXA 600 mg/300 mg comprimidos recubiertos con película | Daniel Podzamczer | Virus de imunodeficiencia humana-1 | | | | |
2010-023192-26: EFFECT OF SWITCHING FROM NRTIS TO MARAVIROC ON NRTI-ASSOCIATED MITCHONDRIAL TOXICITY AND IMMUNE ACTIVATION Auswirkung des Wechsels von NRTIs zu Maraviroc auf NRTI-assoziierte mitochondriale Toxizität und Immunaktivierung |
|
|
| Ongoing | 4 | 80 | Europe | Celcentri, Celcentri, Celcentri | mib Dienstleistungsgesellschaft mbH, ViiV Healthcare GmbH | Increases in inflammatory biomarkers have been associated with various non-AIDS complications such as cardiovascular events. Maraviroc has no known toxic effects on mitochondria and has been shown to reduce immune activation / inflammation in treatment intensification settings. The purpose of this study is to investigate if switching from NRTIs to Maraviroc results in reversal of NRTI-associated mitochondrial toxicity and decreases in markers of immune activation and inflammation. | | | | |
2011-003447-21: Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis |
|
|
| Ongoing | 4 | 280 | Europe | Maraviroc, Celsentri, Celsentri | Camden Provider Services, Pfizer | Prophylaxis and prevention of HIV Infection. | | | | |
2012-000649-11: SSAT046 Addition of Maraviroc to monotherapy Darunavir/Ritonavir study |
|
|
| Ongoing | 4 | 30 | Europe | Darunavir, Ritonavir, Maraviroc, Prezista, Norvir, Celsentri, Prezista, Norvir, Celsentri | St Stephen\'s Aids Trust, St Stephen\'s AIDS Trust, Pfizer Inc | HIV | | | | |
2012-003778-16: The dose and genital tract concentration of Maraviroc needed for protection from HIV infection |
|
|
| Ongoing | 4 | 54 | Europe | Celsentri, Celsentri | Guy\'s & St. Thomas\' NHS Foundation Trust, Pfizer Inc | HIV | | | | |
| Not yet recruiting | 4 | 186 | NA | Placebo for MVC, Maraviroc, MVC, Placebo for DTG, Dolutegravir, DTG | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-1 Infection | 06/17 | 06/18 | | |
2017-004141-24: A study in which people who have HIV and fatty liver disease, who do not drink excessive alcohol, are either asked to take the drug maraviroc on top of their normal anti-HIV medicines or to take their normal anti-HIV medicines alone |
|
|
| Ongoing | 4 | 60 | Europe | Celsentri, Film-coated tablet, Celsentri | Brighton and Sussex University Hospitals NHS Trus | Non-alcoholic fatty liver disease in people living with well-controlled HIV-1 infection, A disease of too much fat laid down in the liver in people who have HIV and do not drink over the recommended limit of alcohol, Diseases [C] - Digestive System Diseases [C06] | | | | |
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos. |
|
|
| Ongoing | 4 | 100 | Europe | lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy | FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare | HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
| Ongoing | 3 | 120 | Europe | CELSENTRI, REYATAZ, NORVIR, TRUVADA, CELSENTRI, REYATAZ, NORVIR, TRUVADA | AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | HIV/ HCV Coinfection | | | | |
2010-019518-25: (Maraviroc ENHancement of Immunological Response): A pilot study of maraviroc as an add-on in patients with reduced CD4 cell count despite full viral suppression |
|
|
| Ongoing | 3 | 20 | Europe | Tablet | AZIENDA OSPEDALIERA \"OSPEDALI RIUNITI DI BERGAMO\" (A.O. DI RILIEVO NAZIONALE) | HIV | | | | |
2011-004435-31: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc. |
|
|
| Ongoing | 3 | 12 | Europe | CELSENTRI 300mg Film coated tablets, CELSENTRI 300mg Film coated tablets | ViiV Healthcare UK Limited, VIIV HEALTHCARE UK LIMITED, ViiV Healthcare | HIV-1 infection | | | | |
2016-003741-29: Study of the use of anti_HIV drugs with reduced neuronal toxicity (including maraviroc) in patients with neurocogntive disorders Utilizzo di farmaci per il trattamento dell'infezione da HIV a ridotta tossicit¿ sui neuroni (incluso maraviroc) in pazienti con disturbi neurocognitivi |
|
|
| Not yet recruiting | 3 | 76 | Europe | CELSENTRI, EMTRIVA, MARAVIROC, EMTRIVA, Coated tablet, CELSENTRI - 300 MG COMPRESSA RIVESTITA CON FILM - USO ORALE BLISTER (PVC/ALU) 60 COMPRESSE, REZOLSTA - 800 MG/ 150 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE-FLACONE (HDPE)- 30 COMPRESSE, EMTRIVA - 30 CAPSULE RIGIDE IN FLACONE DA 200 MG | A.S.L. TO 2, Viiv Healthcare | HIV-infection, HIV-associated neurocognitive disorders Infezione da HIV, disordini neurocognitivi HIV-correlati, HIV-infection with neurocognitive problems Infezione da HIV con problemi neurocognitivi, Diseases [C] - Virus Diseases [C02] | | | | |
| Withdrawn | 3 | 14 | Europe | maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD), CELSENTRI, REYATAZ, NORVIR | University of Turin, Italy, Alfred Health
| Heart failure | 12/17 | 12/17 | | |
NCT00791700 / 2008-006873-33: An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children |
|
|
| Active, not recruiting | 2 | 103 | Europe, US, RoW | Maraviroc, Selzentry | ViiV Healthcare, Pfizer | Human Immunodeficiency Virus | 04/15 | 06/23 | | |
2008-006287-11: Virologic efficacy of Maraviroc in adult naive HIV patients with HIV-RNA>= 1000 copies/ml |
|
|
| Ongoing | 2 | 60 | Europe | CELSENTRI, TRUVADA, KALETRA, CELSENTRI, TRUVADA, KALETRA | OSPEDALE S. RAFFAELE | naive HIV affected patients | | | | |
2009-016480-11: “No Nuc, No Boost” : A phase 2 pilot study of simplification by Maraviroc-Raltegravir following 6 months of treatment with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in naive patients infected by CCR5 HIV-1 |
|
|
| Ongoing | 2 | 40 | Europe | Raltegravir, Maraviroc, Tenofovir/Emtricitabine, ISENTRESS, CELSENTRI, TRUVADA, ISENTRESS, CELSENTRI, TRUVADA | P Pierre Dellamonica | HIV naïve patients, CCR5 tropism, with CD4 > 200/mm3 and HIV RNA < 100 000 copy/ml. | | | | |
2009-014406-34: International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression |
|
|
| Ongoing | 2 | 12 | Europe | GLYCOSYLATED RECOMBINANT HUMAN INTERLEUKIN-7, MARAVIROC, RALTEGRAVIR, CYT107, SELZENTRY, CELSENTRI, ISENTRESS, SELZENTRY, CELSENTRI, ISENTRESS | ORVACS, KEYRUS BIOPHARMA, , Bettencourt-Schueller Foundation | HIV-1 Infection | | | | |
2016-003575-21: MAVMET: A research study exploring whether MAraViroc, a licensed treatment for HIV infection and METformin, a licensed treatment for diabetes, are effective and safe at reducing the amount of fat in the liver. |
|
|
| Ongoing | 2 | 88 | Europe | Metformin, Celsentri, metformin, metformin, maraviroc, Film-coated tablet, Metformin, Celsentri, metformin | MRC Clinical Trials Unit at UCL, Viiv Healthcare | Hepatic steatosis in adults with chronic HIV-1 infection, HIV-1- infected patients with non-alcoholic fatty liver disease, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Ongoing | 2 | 30 | Europe | Celsentri, Film-coated tablet, Celsentri | Imperial College London | Non alcoholic steatohepatitis (NASH) in patients with HIV mono-infection., Fatty liver disease in patients with HIV infection., Diseases [C] - Digestive System Diseases [C06] | | | | |
| Completed | 2 | 10 | RoW | Maraviroc 300 mg | Tel-Aviv Sourasky Medical Center | Post-stroke Depression | 08/22 | 08/22 | | |
NCT04966429: Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment |
|
|
| Recruiting | 2 | 150 | RoW | Maraviroc | Tel-Aviv Sourasky Medical Center, Hadassah Medical Center, Soroka University Medical Center | Post Stroke Cognitive Impairment | 04/24 | 06/24 | | |
| Recruiting | 2 | 120 | Canada | Maraviroc, Celsentri, Exercise Program, Placebo, "Sugar" Pill, Activity Sensor, Motor Learning | University of Calgary, University Health Network, Toronto, University of California, Los Angeles, Sunnybrook Health Sciences Centre, University of British Columbia, Memorial University of Newfoundland, Dalhousie University, Parkwood Hospital, London, Ontario, Riverview Health Centre Foundation, The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation | Stroke | 12/24 | 12/24 | | |
NCT05470491: Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV |
|
|
| Suspended | 1/2 | 3 | US | RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc | National Cancer Institute (NCI) | HIV, Hematologic Malignancies | 07/26 | 07/27 | | |
ChiCTR-OIC-17013778: Phase I trial of PD-1 combination with CCR5 inhibition for the treatment of metastatic gastric cancer |
|
|
| Not yet recruiting | 1 | 20 | China | Pembrolizumab plus Maraviroc | Shanghai Tenth Peoples' Hospital ; Shanghai Tenth Peoples' Hospital, Shanghai Science and Technology Committee | Gastric Cancer | | | | |
NCT04721301: Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial |
|
|
| Completed | 1 | 50 | Europe | Nivolumab plus Ipilimumab plus Maraviroc | University Hospital Heidelberg, German Cancer Research Center | Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic | 03/23 | 03/23 | | |
NCT00801515: A Compassionate Access Protocol For Those Patients Who Have Completed A4001029 |
|
|
| No Longer Available | N/A | | Canada | Maraviroc, Celsentri | ViiV Healthcare, Pfizer | HIV | 07/11 | 07/11 | | |
NCT01776996: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc |
|
|
| No Longer Available | N/A | | Europe, RoW | Continued Access Arm | ViiV Healthcare, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | | | | |
NCT00992654: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India |
|
|
| No Longer Available | N/A | | NA | Open Label Treatment Access: Maraviroc, Maraviroc, Celsentri, Selzentry | ViiV Healthcare, Pfizer | Human Immunodeficiency Virus (HIV) | | | | |